Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 259 | 84 | 170 |
| Samples | 241 | 72 | 164 |
| Peptides | 177 | 52 | 131 |
Function
ADRA1B · Adrenoceptor alpha 1B
Alpha-1-adrenergic receptors (alpha-1-ARs) are members of the G protein-coupled receptor superfamily. They activate mitogenic responses and regulate growth and proliferation of many cells. There are 3 alpha-1-AR subtypes: alpha-1A, -1B and -1D, all of which signal through the Gq/11 family of G-proteins and different subtypes show different patterns of activation. This gene encodes alpha-1B-adrenergic receptor, which induces neoplastic transformation when transfected into NIH 3T3 fibroblasts and other cell lines. Thus, this normal cellular gene is identified as a protooncogene. This gene comprises 2 exons and a single large intron of at least 20 kb that interrupts the coding region. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000306675 | P35368 | 259 | 177 |
Gene Properties
Recurrent Mutations
All 177 amino-acid changes on canonical ENST00000306675 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ADRA1B · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ADRA1B – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 7/40 18% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 13/612 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Plasma Cell Myeloma | 6/44 14% | 0/305 0% |
| Melanoma | 7/210 3% | 20/1899 1% |
| Gastric Carcinoma | 0/74 0% | 24/1809 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Colorectal Carcinoma | 9/143 6% | 25/3239 1% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 13/1390 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Bladder Carcinoma | 4/58 7% | 2/956 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Neuroendocrine Tumour | 2/154 1% | 2/577 0% |
| Other Sarcomas | 1/69 1% | 3/699 0% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Other Solid Cancers | 2/94 2% | 5/1515 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Biliary Tract Carcinoma | 0/54 0% | 4/950 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Ovarian Carcinoma | 3/109 3% | 1/998 0% |
| Head and Neck Carcinoma | 2/85 2% | 4/1574 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 7/2550 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| B-Lymphoblastic Leukemia | 5/55 9% | 2/2640 0% |
| Prostate Carcinoma | 2/13 15% | 3/2105 0% |
| Breast Carcinoma | 5/144 3% | 2/3264 0% |
| Hepatocellular Carcinoma | 0/46 0% | 4/2210 0% |
Mutation Distribution
Where ADRA1B is mutated · all tissues, split by cell line vs tissue
How many mutations in ADRA1B were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 259 mutations in ADRA1B
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|